News 
Market Data 
Discover
Replies to post #588211 on NorthWest Biotherapeutics Inc (NWBO)
Raymond M. Sarola is of counsel at Cohen Milstein and a member of the Whistleblower/False Claims Act and the Ethics and Fiduciary Counseling practices. He represents whistleblowers in qui tam cases brought under the federal and state False Claims Act statutes in industries that conduct business with the government, including health care, defense, and financial services. As a member of the firm’s Ethics and Fiduciary Counseling practice, Mr. Sarola calls on his experience as a trustee on the New York City pension fund boards in counseling public pension funds fiduciary issues.
Prior to joining Cohen Milstein, Mr. Sarola served as Senior Policy Advisor & Counsel in the Mayor's Office of the City of New York, where he represented the Mayor and Commissioner of Finance on the boards of the City's pension systems and deferred compensation plan and advised on legal issues regarding pension investments, benefit payments, securities litigation and corporate governance initiatives. Previously, Mr. Sarola was a litigation associate at a noted defendants’ firm, where he focused on securities, antitrust, and other complex commercial litigation, and internal investigations.
Mr. Sarola’s government service and corporate defense litigation experience has been invaluable to his role in counseling clients in their claims against the government and corporate entities.
Mr. Sarola has been involved in high-profile whistleblower cases including:
* United States et al., ex rel. Lauren Kieff, v. Wyeth: Mr. Sarola assisted in this qui tam action against the pharmaceutical company Wyeth, resulting in a $784.6 million settlement, the seventh-largest False Claims Act recovery on record.
* United States ex rel. Davis, et al. v. Southern SNF Management, Inc. et al.: Mr. Sarola was actively involved in this qui tam case in which the whistleblowers alleged the skilled nursing facilities in which they worked were involved in a multi-year scheme to increase the facilities’ Medicare reimbursement by assigning Medicare patients to levels of therapy far greater than medically appropriate and billing Medicare at the higher amounts associated with this unnecessary therapy. The government recovered $10 million from the defendants.
OTHER PROFESSIONAL EXPERIENCE
* Senior Policy Advisor and Counsel, Mayor's Office, City of New York, 2010-2014
* Intern, the Hon. Judge Clarence Newcomer, U.S. District Court for the Eastern District of Pennsylvania, 2003
CURRENT CASES
Northwest Biotherapeutics, Inc. Securities Litigation
